Evidence map›Paper›PMID 30023123›Full record

ArticleJournal of thoracic disease2018

MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway.

Ramon Andrade De Mello, Pedro Nazareth Aguiar, Hakaru Tadokoro, Tállita Meciany Farias-Vieira, Pedro Castelo-Branco, Gilberto de Lima Lopes, Daniel Humberto Pozza

Open access · hybridAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Treatment Sequencing Strategies in Lung Cancer.Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022
    Article
  4. PGK1 : An Essential Player in Modulating Tumor Metabolism.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  5. Review
  6. Review
  7. PGK1-mediated cancer progression and drug resistance.American journal of cancer research · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Ramon Andrade De MelloAlgarve Biomedical Center, Department of Biomedical Sciences and Medicine, Division of Oncology, University of Algarve, 8005-139 Faro, Portugal.
Pedro Nazareth AguiarPhD Fellowship Program, Faculdade de Medicina do ABC, Santo André, SP, Brazil.
Hakaru TadokoroDivision of Medical Oncology, São Paulo University Hospital, Federal University of São Paulo (EPM/UNIFESP), São Paulo, SP, Brazil.
Tállita Meciany Farias-VieiraMSL at Hoffmann-La Roche, São Paulo, SP, Brazil.
Pedro Castelo-BrancoAlgarve Biomedical Center, Department of Biomedical Sciences and Medicine, Division of Oncology, University of Algarve, 8005-139 Faro, Portugal.
Gilberto de Lima LopesSylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Daniel Humberto PozzaFaculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Universidade do Porto · PTFaculdade de Medicina do ABC · BRMicrosoft (Brazil) · BRUniversidade Federal de São Paulo · BRUniversity of Algarve · PTUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30023123
PMCPMC6036006
OpenAlexW2802291591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.